Brief introduction explaining scope and methodology.
#1
Columbus, Ohio
#2
Regensburg, Bavaria
#3
Istanbul, Istanbul
In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.
July 16, 2026
In two population-based cohorts, metabolically unhealthy status generally showed higher dementia risk estimates, while metabolically healthy obesity was not associated with increased risk in primary analyses.
June 29, 2026
Oral orforglipron could be more effective in reducing hemoglobin A1c and body weight, with no increased risk of hypoglycemia in patients with inadequately controlled type 2 diabetes.
June 12, 2026
